Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.41M | 1.39M | 1.61M | 1.73M | 1.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.74M | 2.65M | 2.72M | 2.88M | 2.44M |
| Operating Income | -2.74M | -2.65M | -2.72M | -2.88M | -2.44M |
| Income Before Tax | -2.63M | -2.54M | -2.59M | -2.72M | -2.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.63M | -2.54M | -2.59M | -2.72M | -2.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 19.00K | 20.00K | 20.00K | 27.00K | 22.00K |
| Net Income | -2.61M | -2.52M | -2.57M | -2.70M | -2.26M |
| EBIT | -2.74M | -2.65M | -2.72M | -2.88M | -2.44M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.08 | -0.07 | -0.08 | -0.08 | -0.07 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 |
| EPS Diluted | -0.08 | -0.07 | -0.08 | -0.08 | -0.07 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 |
| Average Basic Shares Outstanding | 34.18M | 33.59M | 33.24M | 32.94M | 32.48M |
| Average Diluted Shares Outstanding | 34.18M | 33.59M | 33.24M | 32.94M | 32.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |